The progression of dementia in people with young-onset dementia (YOD) is relatively unknown.
Objective:
To investigate the progression of dementia and cognitive decline in the three most common subtypes in YOD and to explore which factors are associated with this course.
Methods:
The course of dementia was examined in 198 people with YOD. The primary outcomes were cognitive function, as assessed by the Mini-Mental State Examination (MMSE) and dementia severity, as assessed by the Global Deterioration Scale (GDS). Mixed-model analyses were used to explore factors associated with the course of dementia of the diagnostic sub-types.
Results:
The mean overall two-year progression of dementia severity was 0.9 GDS points, this was a statistically significant change (p = 0.012) and was not significantly different for the three dementia subtypes. The mean overall two-year decline in cognitive function was 1.6 points on the MMSE. The differences in cognitive decline were statistically significant (p = 0.046) among the three diagnosis groups, AD participants showed the greatest decline, of 2.3 points. In addition to lower education (p = 0.010), higher scores on the Neuropsychiatric Inventory (NPI) sub-syndromes psychosis (p < 0.001) and hyperactivity (p = 0.002) were associated with higher rates of cognitive decline. In contrast, higher scores on the NPI affect cluster were associated with lower levels of cognitive decline (p < 0.001).
Conclusion:
Different YOD subtypes show different rates of decline in cognitive functioning, and this decline seems less progressive compared to those observed in studies in late-onset AD. Further research is needed to evaluate whether managing neuropsychiatric symptoms can positively influence the decline of cognitive function.
StanleyK, WalkerZ (2014) Do patients with young onset Alzheimer’s disease deteriorate faster than those with late onset Alzheimer’s disease? A review of the literature. Int Psychogeriatr26, 1945–1953.
2.
HollandD, DesikanRS, DaleAM, McEvoyLK, Alzheimer’s Disease Neuroimaging Initiative (2012) Rates of decline in Alzheimer disease decrease with age. PLoS One7, e42325.
3.
SmitsLL, van HartenAC, PijnenburgYA, KoedamEL, BouwmanFH, SistermansN, ReulingIE, PrinsND, LemstraAW, ScheltensP, van der FlierWM (2015) Trajectories of cognitive decline in different types of dementia. Psychol Med45, 1051–1059.
4.
EustaceA, CoenR, WalshC, CunninghamCJ, WalshJB, CoakleyD, LawlorBA (2002) A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer’s disease. Int J Geriatr Psychiatry17, 968–973.
5.
HerrmannN, HarimotoT, BalshawR, LanctotKL, Canadian Outcomes Study in Dementia Investigators (2015) Risk factors for progression of Alzheimer disease in a Canadian population: The Canadian Outcomes Study in Dementia (COSID). Can J Psychiatry60, 189–199.
6.
HeymanA, PetersonB, FillenbaumG, PieperC (1997) Predictors of time to institutionalization of patients with Alzheimer’s disease: The CERAD experience, part XVII. Neurology48, 1304–1309.
7.
LopezOL, WisniewskiSR, BeckerJT, BollerF, DeKoskyST (1999) Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol56, 1266–1272.
8.
RasmussonDX, CarsonKA, BrookmeyerR, KawasC, BrandtJ (1996) Predicting rate of cognitive decline in probable Alzheimer’s disease. Brain Cogn31, 133–147.
9.
SelbaekG, EngedalK, BenthJS, BerghS (2014) The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period. Int Psychogeriatr26, 81–91.
10.
HanL, ColeM, BellavanceF, McCuskerJ, PrimeauF (2000) Tracking cognitive decline in Alzheimer’s disease using the mini-mental state examination: A meta-analysis. Int Psychogeriatr12, 231–247.
WilkoszPA, SeltmanHJ, DevlinB, WeamerEA, LopezOL, DeKoskyST, SweetRA (2010) Trajectories of cognitive decline in Alzheimer’s disease. Int Psychogeriatr22, 281–290.
13.
GronningH, RahmaniA, GyllenborgJ, DessauRB, HoghP (2012) Does Alzheimer’s disease with early onset progress faster than with late onset? A case-control study of clinical progression and cerebrospinal fluid biomarkers. Dement Geriatr Cogn Disord33, 111–117.
14.
PanegyresPK, ChenHY (2013) Differences between early and late onset Alzheimer’s disease. Am J Neurodegener Dis2, 300–306.
15.
van der VliesAE, KoedamEL, PijnenburgYA, TwiskJW, ScheltensP, van der FlierWM (2009) Most rapid cognitive decline in APOE epsilon4 negative Alzheimer’s disease with early onset. Psychol Med39, 1907–1911.
16.
JacobsD, SanoM, MarderK, BellK, BylsmaF, LaflecheG, AlbertM, BrandtJ, SternY (1994) Age at onset of Alzheimer’s disease: Relation to pattern of cognitive dysfunction and rate of decline. Neurology44, 1215–1220.
17.
CanevelliM, AdaliN, CantetC, AndrieuS, BrunoG, CesariM, VellasB, ICTUS/DSA Group (2013) Impact of behavioral subsyndromes on cognitive decline in Alzheimer’s disease: Data from the ICTUS study. J Neurol260, 1859–1865.
18.
TollefsonGD, Montague-ClouseJ, LancasterSP (1991) The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci3, 314–319.
19.
TuneLE (2001) Anticholinergic effects of medication in elderly patients. J Clin Psychiatry62(Suppl 21), 11–14.
20.
WardA, CaroJJ, KelleyH, EgglestonA, MolloyW (2002) Describing cognitive decline of patients at the mild or moderate stages of Alzheimer’s disease using the standardized MMSE. Int Psychogeriatr14, 249–258.
21.
SniderBJ, FaganAM, RoeC, ShahAR, GrantEA, XiongC, MorrisJC, HoltzmanDM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol66, 638–645.
22.
StaekenborgSS, PijnenburgYA, LemstraAW, ScheltensP, Vd FlierWM (2016) Dementia and Rapid Mortality: Who is at Risk?. J Alzheimers Dis53, 135–142.
23.
KoopmansRT, ReindersR, van VlietD, VerheyFR, de VugtME, BorH, BakkerC (2014) Prevalence and correlates of psychotropic drug use in community-dwelling people with young-onset dementia: The NeedYD-study. Int Psychogeriatr26, 1983–1989.
24.
McShaneR, KeeneJ, GedlingK, FairburnC, JacobyR, HopeT (1997) Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ314, 266–270.
25.
PerryEK, KilfordL, LeesAJ, BurnDJ, PerryRH (2003) Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol54, 235–238.
26.
LivingstonG, WalkerAE, KatonaCL, CooperC (2007) Antipsychotics and cognitive decline in Alzheimer’s disease: The LASER-Alzheimer’s disease longitudinal study. J Neurol Neurosurg Psychiatry78, 25–29.
27.
MahL, SzabuniewiczC, FioccoAJ (2016) Can anxiety damage the brain?. Curr Opin Psychiatry29, 56–63.
28.
van VlietD, BakkerC, KoopmansRT, Vernooij-DassenMJ, VerheyFR, de VugtME (2010) Research protocol of the NeedYD-study (Needs in Young onset Dementia): A prospective cohort study on the needs and course of early onset dementia. BMC Geriatr10, 13.
29.
ReisbergB, FerrisSH, de LeonMJ, CrookT (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry139, 1136–1139.
30.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
31.
TombaughTN, McIntyreNJ (1992) The mini-mental state examination: A comprehensive review. J Am Geriatr Soc40, 922–935.
32.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders-Text revision: DSM-IV-TR. American Psychiatric Association, Arlington.
33.
ErkinjunttiT (1994) Clinical criteria for vascular dementia: The NINDS-AIREN criteria. Dementia5, 189–192.
34.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
WHO Collaborating Centre for Drug Statistics Methodology (2014) Guidelines for ATC classification and DDD assignment, 2015.
37.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
38.
KatMG, de JongheJF, AaltenP, KalisvaartCJ, DroesRM, VerheyFR (2002) [Neuropsychiatric symptoms of dementia: Psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI)]. Tijdschr Gerontol Geriatr33, 150–155.
39.
AaltenP, VerheyFR, BozikiM, BrugnoloA, BullockR, ByrneEJ, CamusV, CaputoM, CollinsD, De DeynPP, ElinaK, FrisoniG, HolmesC, HurtC, MarriottA, MecocciP, NobiliF, OussetPJ, ReynishE, SalmonE, TsolakiM, VellasB, RobertPH (2008) Consistency of neuropsychiatric syndromes across dementias: Results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord25, 1–8.
40.
PerraultA, WolfsonC, EganM, RockwoodK, HoganDB (2002) Prognostic factors for functional independence in older adults with mild dementia: Results from the canadian study of health and aging. Alzheimer Dis Assoc Disord16, 239–247.
41.
BrodatyH, WoodwardM, BoundyK, AmesD, BalshawR, Prime Study Group (2011) Patients in Australian Memory Clinics: Baseline characteristics and predictors of decline at six months. Int Psychogeriatr23, 1086–1096.
42.
MarquesSC, OliveiraCR, OuteiroTF, PereiraCM (2010) Alzheimer’s disease: The quest to understand complexity. J Alzheimers Dis21, 373–383.
43.
NovaisF, StarksteinS (2015) Phenomenology of depression in Alzheimer’s disease. J Alzheimers Dis47, 845–855.
44.
SierksmaAS, van den HoveDL, SteinbuschHW, PrickaertsJ (2010) Major depression, cognitive dysfunction and Alzheimer’s disease: Is there a link?. Eur J Pharmacol626, 72–82.
45.
JonesHE, JoshiA, ShenkinS, MeadGE (2016) The effect of treatment with selective serotonin reuptake inhibitors in comparison to placebo in the progression of dementia: A systematic review and meta-analysis. Age Ageing45, 448–456.
46.
KonishiK, HoriK, UchidaH, WatanabeK, TominagaI, KimuraM, HosoyamadaM, ShibasakiT, KataokaA, HachisuM (2010) Adverse effects of anticholinergic activity on cognitive functions in Alzheimer’s disease. Psychogeriatrics10, 34–38.
47.
LohrJB, CaligiuriMP, EdsonR, LavoriP, AdlerLA, RotrosenJ, HitzemannR (2002) Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: Results from Veterans Affairs Cooperative Study 394. J Clin Psychopharmacol22, 196–200.
48.
NortonS, MatthewsFE, BarnesDE, YaffeK, BrayneC (2014) Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neurol13, 788–794.
49.
SaundersJA, Morrow-HowelN, SpitznagelE, DoréP, ProctorEK, PescarinoR (2006) Imputing missing data: A comparison of methods for social work researchers. Social Work Res30, 19–32.
50.
BurnsRA, ButterworthP, KielyKM, BielakAA, LuszczMA, MitchellP, ChristensenH, Von SandenC, AnsteyKJ (2011) Multiple imputation was an efficient method for harmonizing the Mini-Mental State Examination with missing item-level data. J Clin Epidemiol64, 787–793.
51.
HoltzmanDM, MorrisJC, GoateAM (2011) Alzheimer’s disease: The challenge of the second century. Sci Transl Med3, 77sr71.
52.
RossorMN, FoxNC, MummeryCJ, SchottJM, WarrenJD (2010) The diagnosis of young-onset dementia. Lancet Neurol9, 793–806.
53.
WangF, FengTY, YangS, PreterM, ZhouJN, WangXP (2016) Drug therapy for behavioral and psychological symptoms of dementia. Curr Neuropharmacol14, 307–313.
